PF-Atlas › Clinical Trials › NCT01069510
Spironolactone in Adult Congenital Heart Disease
Spironolactone 25mg · Phase 2
Registry ID
NCT01069510
Phase
Phase 2
Status
Completed
Drug / intervention
Spironolactone 25mg
Sponsor
Oregon Health and Science University
Start
2010-02
Enrollment
40
Locations
1
About this trial
The purpose of this study is to see if the study drug called spironolactone reduces fibrous (stiffening) in heart muscle tissue and improves heart function. Subjects from the study titled "Heart Failure in Congenital Heart Disease: the role of myocardial fibrosis" who have evidence of heart dysfunction and/or evidence of fibrosis (stiffening) in the heart muscle will be asked to take part in this study.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01069510 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.